Affordable Access

Publisher Website

Oncolytic Viruses

Advances in Virology
Hindawi Publishing Corporation
Publication Date
DOI: 10.1155/2012/320206
  • Editorial
  • Biology
  • Chemistry
  • Engineering
  • Medicine


Hindawi Publishing Corporation Advances in Virology Volume 2012, Article ID 320206, 2 pages doi:10.1155/2012/320206 Editorial Oncolytic Viruses Nanhai G. Chen,1, 2 Aladar A. Szalay,1, 2, 3, 4, 5 R. Mark L. Buller,6 and Ulrich M. Lauer7 1Genelux Corporation, San Diego Science Center, San Diego, CA 92019, USA 2Department of Radiation Oncology, Rebecca and John Moores Comprehensive Cancer Center, University of California, San Diego, CA 92093, USA 3Department of Biochemistry, University of Wuerzburg, 97074 Wuerzburg, Germany 4Rudolf Virchow Center for Experimental Biomedicine, University of Wuerzburg, 97078 Wuerzburg, Germany 5 Institute for Molecular Infection Biology, University of Wuerzburg, 97078 Wuerzburg, Germany 6Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, St. Louis, MO 63104, USA 7Department of Gastroenterology and Hepatology, Medical University Hospital, 72076 Tu¨bingen, Germany Correspondence should be addressed to Nanhai G. Chen, [email protected] Received 7 March 2012; Accepted 7 March 2012 Copyright © 2012 Nanhai G. Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Oncolytic viruses, by definition, are viruses that are capable of infecting and selectively replicating in cancer cells, even- tually leading to cell death without harming healthy cells. The concept of using viruses to treat cancer dates back over a century. There was renewed interest in oncolytic virotherapy in the 1990s after the first genetically engineered oncolytic virus, a herpes simplex virus-1 thymidine kinase mutant, was reported in 1991. Over the last two decades great progress has been made in this field, and several oncolytic viruses have entered into clinical trials. This special issue on oncolytic viruses addresses some of the challenges that need to be overc

There are no comments yet on this publication. Be the first to share your thoughts.


Seen <100 times